Welcome to our dedicated page for Silexion Therapeutics Ordinary Shares news (Ticker: SLXN), a resource for investors and traders seeking the latest updates and insights on Silexion Therapeutics Ordinary Shares stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Silexion Therapeutics Ordinary Shares's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Silexion Therapeutics Ordinary Shares's position in the market.
Silexion Therapeutics (NASDAQ: SLXN) has unveiled promising preclinical data for SIL-204, its next-generation siRNA candidate targeting KRAS-driven cancers. The data demonstrates significant synergy between SIL-204 and first-line chemotherapy agents, including 5-fluorouracil, irinotecan, and gemcitabine.
In human pancreatic tumor cell models with KRAS G12D mutations, SIL-204 enhanced the effectiveness of standard therapies, showing greater reductions in cancer cell confluence compared to chemotherapy alone. This is particularly significant as KRAS mutations are present in over 90% of pancreatic cancer cases.
Building on its first-generation LODER™ platform's success in Phase 2 trials, SIL-204 targets a broader spectrum of KRAS mutations. The company plans to begin toxicology studies soon, with Phase 2/3 trials scheduled for 2026. Additionally, Silexion announced a $5 million public offering to support its research efforts.
Silexion Therapeutics (NASDAQ: SLXN), a clinical-stage biotech focused on RNA interference therapies for KRAS-driven cancers, has announced the pricing of a $5.0 million public offering. The offering consists of 3,703,703 ordinary shares (or equivalents) and warrants to purchase up to 3,703,703 ordinary shares at a combined price of $1.35 per share and accompanying warrant.
The warrants will have an exercise price of $1.35 per share, will be immediately exercisable, and will expire in five years. The offering is expected to close around January 17, 2025, with H.C. Wainwright & Co. acting as exclusive placement agent. The company plans to use the proceeds to advance pre-clinical studies and for general corporate purposes.
Silexion Therapeutics (NASDAQ: SLXN) has announced promising new preclinical results for its second-generation siRNA candidate, SIL-204, showing significant synergistic activity when combined with standard pancreatic cancer chemotherapies. The data demonstrates that SIL-204 enhances the effectiveness of 5-fluorouracil, irinotecan, and gemcitabine in human pancreatic tumor cell lines with KRAS G12D mutations.
The combination of SIL-204 with 5-fluorouracil and irinotecan achieved a significant reduction in cancer cell confluence after three days compared to chemotherapy alone (p < 0.0005). These results build upon previous successes with the company's first-generation product, LODER™, which demonstrated improved overall survival in Phase 2 trials.
Silexion plans to initiate toxicology studies for SIL-204 in the coming months and advance to Phase 2/3 clinical trials in the first half of 2026, focusing on locally advanced pancreatic cancer (LAPC). The company also plans to begin preclinical studies for SIL-204 in colorectal cancer models.
Silexion Therapeutics (NASDAQ: SLXN) has announced its upcoming presentation at the 2025 ASCO Gastrointestinal Cancers Symposium in San Francisco from January 23-25, 2025. The company will present data on SIL-204, their RNA interference therapy targeting KRAS-driven cancers.
The presentation, titled 'SIL-204 siRNA free and encapsulated in extended release microparticles for the treatment of localized and systemic cancer that harbors a KRAS G12x, Q61H, or G13D mutation,' will be delivered by Mitchell Shirvan, Ph.D. during the Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract session on January 24, 2025, from 11:30 AM to 1:00 PM PST.
The abstract will be published on the symposium's website on January 21, 2025, at 5:00 p.m. ET, and the poster will subsequently be available on Silexion's website under the 'Our Science' section.
Silexion Therapeutics (NASDAQ: SLXN) is advancing precision oncology through its collaboration with Evonik, developing a long-acting PLGA microparticle formulation for SIL-204, its next-generation siRNA candidate targeting KRAS mutations. Preclinical studies demonstrated high efficacy in reducing tumor size in KRAS-mutated pancreatic cancer models.
The company's RNAi approach silences KRAS mutations at the genetic level, targeting a broader range of mutations (pan-G12x and G13D) with potential applications in pancreatic, colorectal, and lung cancers. This advancement comes amid surging oncology M&A activity, exemplified by Pfizer's $43 billion Seagen acquisition and AbbVie's $10.1 billion Immunogen purchase.
The KRAS inhibitor market is projected to grow at 36% CAGR, reaching $10 billion by 2032. Silexion aims to advance SIL-204 into Phase 2/3 trials by 2025-2026.
Silexion Therapeutics (NASDAQ: SLXN) has announced its collaboration with Evonik for developing an advanced siRNA formulation for cancer treatment. The partnership focuses on creating a long-acting siRNA PLGA microparticle formulation for SIL-204, Silexion's next-generation siRNA candidate.
The formulation, utilizing Evonik's proprietary biodegradable RESOMER® technology, has shown high efficacy in preclinical models using mice with human pancreatic tumor cell lines carrying various KRAS mutations. The collaboration aims to enhance cancer treatment through sustained-release RNAi therapy, specifically targeting KRAS mutations, a significant challenge in oncology.
Silexion Therapeutics (NASDAQ: SLXN) has appointed Prof. Amnon Peled as an independent director to its Board of Directors. Prof. Peled, a globally recognized authority in stem cell biology, immunology, and cancer therapeutics, will serve on the company's audit, compensation, and nominating and corporate governance committees. The appointment strengthens Silexion's scientific expertise as it develops RNA interference (RNAi) therapies for KRAS-driven cancers.
The Board unanimously approved his appointment, citing his extensive experience in advancing novel cancer therapies from discovery to FDA approval. The appointment also ensures Silexion's compliance with Nasdaq's listing requirements by maintaining a fully constituted audit committee.
Silexion Therapeutics (NASDAQ: SLXN) announced a 1-for-9 reverse share split of its ordinary shares, effective after market close on November 27, 2024. Trading on a split-adjusted basis will begin on November 29, 2024, under the same ticker symbol. The par value will increase from $0.0001 to $0.0009 per share, with fractional shares rounded up to whole shares. The move aims to maintain Nasdaq listing compliance and address short-term share price volatility following their business combination. Shareholders with book-entry shares or holding through brokers need not take action as adjustments will be automatic.
Silexion Therapeutics (NASDAQ: SLXN), a clinical-stage biotech focused on developing RNA interference therapies for KRAS-driven cancers, has announced its participation in the Noble Capital Markets 20th Annual Emerging Growth Equity Conference. The event will take place December 3-4, 2024, in Boca Raton, Florida.
CEO Ilan Hadar will present "Transforming Cancer Care: Silexion Therapeutics' Innovative Approach to Pancreatic Cancer" on December 4 at 11:30 am. A replay will be available on the company's website. Management will also be available for one-on-one meetings with interested investors during the conference.
Silexion Therapeutics (NASDAQ: SLXN) has reported significant breakthroughs in preclinical studies for its second-generation siRNA candidate, SIL-204. The latest findings show that the SIL-204-microparticle formulation can inhibit growth and induce necrosis in human pancreatic cell lines with the KRAS G12D mutation, which represents the largest segment of pancreatic cancer subtypes.
Key findings include substantial tumor reduction in mouse xenograft studies with a single administration of SIL-204 encapsulated in an extended-release formulation, and a superior extended-release profile resulting from the transition to PLGA microparticles. Silexion plans to initiate toxicology studies soon and aims to advance SIL-204 into Phase 2/3 clinical trials in the first half of 2026, focusing on locally advanced pancreatic cancer (LAPC).
FAQ
What is the current stock price of Silexion Therapeutics Ordinary Shares (SLXN)?
What is the market cap of Silexion Therapeutics Ordinary Shares (SLXN)?
